RGRN-305

N/A

Report date: 2025/01/11 20:00:12
NME

Base Information

Drug NameRGRN-305
Drug Alias NameRGRN-305BEBT-305(Curis)MC2-32CU-0305CUDC-305 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsPlaque psoriasisSolid tumoursPsoriasis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkUnited Kingdom +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCuris Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesRegranion LLCAarhus University HospitalMc2 Therapeutics Ltd +[4] 
Inactive CompaniesDebiopharm International Sa
Active IndicationsPlaque psoriasisPyoderma GangrenosumHidradenitis Suppurativa
Inactive IndicationsSolid tumoursPsoriasisCarcinoma, Non-Small-Cell Lung +[5] 

Other Information

ATC CodeN/A
Related LinksN/A